Trials / Unknown
UnknownNCT03451942
The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal
The Clinical Study of FLOT Regimen Conversion Therapy of Her-2 Negative and Single Site Metastasis Adenocarcinoma of the Stomach / Gastroesophageal
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 112 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate survival benefit of surgical treatment after FLOT regimen conversion therapy of Her-2 Negative and single site metastasis adenocarcinoma of the stomach / gastroesophageal compared with chemotherapy, use relevant biomarkers to evaluate the efficacy of chemotherapy and seek for patients with Her-2 negative and metastatic adenocarcinoma of the stomach / gastroesophageal surviving benefit from surgical treatment after the FLOT regimen conversion therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FLOT regimen chemotherapy | FLOT regimen chemotherapy |
| PROCEDURE | D2 gastric and imaging metastases resection | After received 4 cycles FLOT regimen chemotherapy , D2 gastric resection and imaging metastases resection was performed. Then continue 4 cycles of FLOT regimen chemotherapy (Chemotherapy begins within 4-6 weeks after surgery) |
Timeline
- Start date
- 2018-02-05
- Primary completion
- 2019-09-01
- Completion
- 2021-03-01
- First posted
- 2018-03-02
- Last updated
- 2018-03-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03451942. Inclusion in this directory is not an endorsement.